AMTI(Delisted)
Applied Molecular·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMTI
Applied Molecular Transport Inc.
A clinical-stage biopharmaceutical company that develops novel oral biologic therapies to treat severe autoimmune, metabolic inflammatory diseases
450 East Jamie Court, South San Francisco, CA 94080
--
Applied Molecular Transport Inc., originally incorporated in Delaware in September 2010, is a limited liability company. The Company is a clinical-stage biopharmaceutical company that leverages its proprietary technology platform to design and develop new candidate oral biologic products for the treatment of autoimmune, inflammatory, metabolic and other diseases. Their proprietary technology platform allows them to leverage existing natural cell trafficking pathways to facilitate active transport of therapeutic payloads through the IE barrier. Active transport is an efficient mechanism that utilizes the cell's own machinery to transport material across the IE barrier.
Company Financials
EPS
AMTI has released its 2023 Q3 earnings. EPS was reported at -0.17, versus the expected -0.5, beating expectations. The chart below visualizes how AMTI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
